MASS (Marketing and Sales Solutions Ltd)
Marketing and sales solutions (MASS) is an independent management consultancy, dedicated to ensuring our clients achieve high performance through strategic brand development and implementation excellence. Focused on the pharmaceutical and health-care industries, our objective is to add straight to your bottom line. MASS has two primary areas of focus: Strategic Consulting and Implementation Excellence.
This is a FREE LISTING on PMHUB
Below are full profiles from other companies in related areas
Havas Life London
We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by strategically aligning promotion, medical education and PR across the product…
Advertising, Branding, Clinical Research, Conference/meetings/events, Creative and design, Digital communications, Management consultancies, Market access, Market research, Marketing consultancies, Medical communications, Medical education, Patient support and adherence, Public relations, Regulatory affairs
MDNT
MDNT is a native Digital and Omnichannel agency focused solely on the healthcare, pharma, and life science industries. We’re highly experienced, no nonesense, and very good at what we do.
Onyx Health
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national and international reach. As we understand the healthcare market and…
OPEN Health
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health outcomes and patient wellbeing.
Sciterion
Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make a positive contribution to patient care. Real world experience of…
Company Details
Latest Content from PMHub
Why stigma is a launch risk in rare disease – and what commercial leaders can do about it
White Papers and Resources | March 2, 2026 | Havas Life London
Rare disease launches are complex by nature. Yet one of the most consistent risks we see is rarely treated as a launch issue at all: stigma.
From ‘why’ to ‘how’: patient partnership across age groups in research and publications
White Papers and Resources | February 27, 2026 | Amiculum
By Sarah Mohamad
From Static to Strategic: The 2026 Playbook for Longitudinal Pharma Interaction
Press Releases | February 26, 2026 | Impetus Digital
Stop pushing content at a burnt-out audience and start creating "Digital Magnetism." Join Impetus Digital to unlock the 2026 Engagement Toolkit—a deep dive into the immersive, longitudinal strategies and newly...
Data, Evidence, Education: Tackling the Global Multi‑Trillion‑Dollar Rare Disease Burden
Press Releases | February 25, 2026 | Medscape Education
Rare diseases are individually uncommon, yet together they affect an estimated 300 million+ people worldwide and touch the lives of over one billion when families and caregivers are included. For...
T40: when a number is not just a number
Press Releases | February 23, 2026 | Grace Communications
Proud to be ranked 3rd among the Top 10 UK-focused agencies, along with other categories, Grace Communications finds inspiration in being included in PMLive’s Top 40 Creative Healthcare Agencies 2025.
Why patient engagement must come first in rare disease trials
White Papers and Resources | February 23, 2026 | Cuttsy + Cuttsy
Explore why patient engagement is the cornerstone of successful rare disease trials, emphasising the importance of designing studies around the realities of patients' lives to build trust and improve outcomes.
New Cuttsy+Cuttsy research shows why site support matters more than ever
Press Releases | February 23, 2026 | Cuttsy + Cuttsy
Cuttsy+Cuttsy's upcoming report, 'The site factor: Where protocol meets practice in clinical trials', delves into the critical role of site staff in clinical research, offering insights into their daily challenges,...
#ShortenTheJourney
Press Releases | February 18, 2026 | Medscape Education
For the millions of people living with a rare disease, the path to a diagnosis (if ever received) is often a long and frustrating odyssey. This delay is frequently driven...
Why We Must Stop Normalizing the “Pregnancy Itch”
Press Releases | February 18, 2026 | Medscape Education
In the world of rare diseases, success is often measured by the speed of diagnosis. However, for women facing rare liver conditions like Intrahepatic Cholestasis of Pregnancy (ICP), the medical...
Winning in Pharma: the power of early strategic planning with patients
White Papers and Resources | February 17, 2026 | Amiculum
By Zoë van Helmond